Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 40,813 | 27,614 | 13,076 | 1,871 | 0 |
| Cost of Goods | 3,004 | 1,654 | 1,216 | 377 | N/A |
| Gross Profit | 37,809 | 25,960 | 11,860 | 1,494 | N/A |
| Operating Expenses | 71,115 | 64,298 | 56,526 | 42,806 | 32,821 |
| Operating Income | -33,302 | -37,684 | -44,450 | -40,935 | -32,821 |
| Interest Expense | 2,109 | 983 | 989 | 858 | 815 |
| Other Income | 2,121 | 2,936 | 3,537 | 2,645 | 2,212 |
| Pre-tax Income | -33,290 | -35,731 | -41,902 | -39,148 | -31,424 |
| Net Income Continuous | -33,290 | -35,731 | -41,902 | -39,148 | -31,424 |
| Net Income | $-33,290 | $-35,731 | $-41,902 | $-39,148 | $-31,424 |
| EPS Basic Total Ops | -0.88 | -1.01 | -1.29 | -1.28 | -1.17 |
| EPS Basic Continuous Ops | -0.88 | -1.01 | -1.30 | -1.28 | -1.17 |
| EPS Diluted Total Ops | -0.88 | -1.01 | -1.29 | -1.28 | -1.17 |
| EPS Diluted Continuous Ops | -0.88 | -1.01 | -1.30 | -1.28 | -1.17 |
| EPS Diluted Before Non-Recurring Items | -0.88 | -1.01 | -1.31 | N/A | N/A |
| EBITDA(a) | $-34,260 | $-37,590 | $-44,117 | $-41,077 | $-33,614 |